BioInvent International AB, a Swedish biotechnology company focused on the discovery and development of first-class, novel immune modulator antibodies for cancer immunotherapy, and Transgene, a biotech company designing and developing virus-based immunotherapies to fight cancer, recently announced positive phase 1a data on BT-001 oncolytic virus for the treatment of solid tumors.
BioInvent currently has four drug candidates in five clinical programs ongoing in phase 1/2 trials for the treatment of haematological cancer and solid tumors. The company’s validated FIRST technology platform identifies targets and antibodies that bind to them, generating many promising new drug candidates to drive the company’s own clinical development path and provide licensing and partnership opportunities.
BioInvent generates revenue from research collaborations and licensing agreements with several top pharmaceutical companies, as well as from the production of antibodies for third parties in the company’s fully integrated production units.
We spoke with BioInvent CEO Martin Welschof and Cecilia Hofvander, senior director investor relations.